Biofy, a Brazil-based global leader in AI-driven infectious disease diagnostics, developed a software pipeline using full-genome DNA sequencing and AI on NVIDIA's accelerated computing platform to rapidly identify bacterial infections and predict antibiotic resistance. The system reduced time to treatment recommendation from five days to four hours—a 30x speedup—and increased diagnostic accuracy to 95–97% compared with traditional laboratory tests (PCR + antibiogram) that reach 80% accuracy with a 33% failure rate. Biofy's Abby platform, powered by Oracle Cloud Infrastructure (OCI) and NVIDIA AI infrastructure, runs NVIDIA-accelerated algorithms to assemble bacterial genomes, match them against a database of microbial genomes and resistance markers, and suggest effective antibiotics. The solution improved performance by 50% with NVIDIA GPUs, at up to half the cost of alternative cloud providers. Biofy is a member of the NVIDIA Inception program.